Pfizer (PFE) Misses Q4 EPS by 2c, Offers FY20 Guidance
Pfizer (NYSE: PFE) reported Q4 EPS of $0.55, $0.02 worse than the analyst estimate of $0.57. Revenue for the quarter came in at $12.7 billion versus the consensus estimate of $12.61 billion.
GUIDANCE:
Pfizer sees FY2020 EPS of $2.82-$2.92, versus the consensus of $2.90. Pfizer sees FY2020 revenue of $48.5-50.5 billion, versus the consensus of $49.52 billion.
Revenues | $48.5 to $50.5 billion |
Adjusted Cost of Sales(3) as a Percentage of Revenues | 19.9% to 20.9% |
Adjusted SI&A Expenses(3) | $12.0 to $13.0 billion |
Adjusted R&D Expenses(3) | $8.1 to $8.5 billion |
Adjusted Other (Income)/Deductions(3) | Approximately $800 million of income |
Effective Tax Rate on Adjusted Income(3) | Approximately 15.0% |
Adjusted Diluted EPS(3) | $2.82 to $2.92 |
For earnings history and earnings-related data on Pfizer (PFE) click here.